Skip to main content
    K

    Kalaris Therapeutics, Inc. (KLRS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.46
    -0.12 (-7.30%)

    Market Cap: $37.49M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Kalaris Therapeutics, Inc. (KLRS) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    Kalaris Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$43.44M, operating cash flow was -$38.37M and free cash flow was -$38.57M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$11.03M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $46.15M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0-100.0%N/AN/AN/A
    Dec 2019$165.00K-85.5%100.0%-16182.4%-14447.9%
    Dec 2018$1.14MN/AN/A-316.8%-214.1%
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Revenue$0$0$0$0$0$0$165.00K$1.14M
    Gross profit$0$0$0$0$0$0$165.00KN/A
    Research and development$30.75M$45.04M$133.07M$118.87M$120.73M$49.66M$16.25M$1.70M
    Operating income-$46.15M-$51.73M-$199.90M-$171.20M-$169.82M-$71.31M-$26.70M-$3.60M
    Net income-$43.44M-$69.17M-$190.42M-$168.71M-$171.96M-$69.78M-$23.84M-$2.43M
    EBITDA-$43.79MN/A-$199.58MN/AN/A-$70.54M-$26.50M-$2.43M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Gross profit$0$0$0-$10.00K$0$0$0N/A$0$0$0N/A
    Operating income-$11.81M-$12.39M-$11.83M-$10.80M-$12.74M-$12.26M-$10.35M-$7.13M-$37.85M-$4.19M-$2.56M-$62.41M
    Net income-$11.03M-$11.52M-$10.86M-$10.00M-$11.89M-$11.35M-$10.20M-$22.03M-$38.08M-$5.65M-$3.41M-$59.70M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $316.00K by $97.74M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$121.74M$6.16M$190.80M$277.08M$286.59M$370.82M$139.42M$25.32M
    Current assets$118.81M$2.61M$187.63M$243.05M$253.35M$361.32M$127.31M$25.31M
    Cash and equivalents$98.05M$1.64M$90.12M$106.09M$201.66M$122.66M$61.08M$24.96M
    Total liabilities$42.92M$56.78M$45.02M$52.56M$61.33M$17.76M$17.80M$3.74M
    Short-term debt$316.00K$19.54MN/AN/A$6.59M$3.23M$3.07MN/A
    Long-term debtN/AN/AN/A$3.25MN/AN/AN/AN/A
    Shareholder equity$78.81M-$96.62M$145.78M$224.52M$225.27M$353.06M-$51.50M$21.58M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$89.00M$99.54M$109.81M$121.74M$81.17M$92.84M$103.09M$118.55M$122.53M$130.99M$144.14M$3.33M
    Total liabilities$41.60M$41.87M$41.25M$42.92M$39.31M$39.73M$39.22M$5.24M$1.41M$10.70M$23.70M$48.35M
    Cash and equivalents$47.38M$43.17M$34.43M$98.05M$42.39M$88.43M$100.97M$118.29M$116.86M$104.74M$86.04M$3.17M
    Shareholder equity$47.40M$57.67M$68.56M$78.81M$41.87M$53.12M$63.87M$113.31M$121.12M$120.29M$120.44M-$45.02M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$38.37M-$20.67M-$124.45M-$142.05M-$106.32M-$60.81M-$20.16M$1.94M
    Capital expenditures$200.00K$0$0$0$26.00K$235.00K$339.00K$0
    Free cash flow-$38.57M-$20.67M-$124.45M-$142.05M-$106.34M-$61.05M-$20.49M$1.94M
    Share repurchases$1.67M$0N/AN/AN/A$3.47M$0N/A
    Investing cash flow-$19.72M$0$37.98M-$80.48M$185.98M-$169.50M-$64.64MN/A
    Financing cash flow$155.01M$19.14M$70.50M$126.96M$232.00K$291.98M$120.92M$22.87M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$10.55M-$11.05M-$11.58M-$7.06M-$11.33M-$12.54M-$7.44M-$7.85M-$4.33M-$3.97M-$4.52M-$30.73M
    Capital expendituresN/AN/A$0$17.00K$183.00K$0$0$0$0$0$0$0
    Free cash flowN/AN/A-$11.58M-$7.07M-$11.52M-$12.54M-$7.44M-$7.85M-$4.33M-$3.97M-$4.52M-$30.73M
    Last 12 quarters

    Frequently Asked Questions About KLRS

    What is Kalaris Therapeutics' annual revenue?

    Kalaris Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Kalaris Therapeutics profitable?

    No. Kalaris Therapeutics reported net income of -$43.44M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does KLRS generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$38.37M minus capital expenditures of $200.00K produced free cash flow of -$38.57M.

    How much debt does Kalaris Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $316.00K and cash and equivalents of $98.05M.